Last update :
18/04/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Antibiotic   Tobramycin sulfate  
Injection
Aerosol Eye-drops Oral solution
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Bactob India
Beltob India
Bramicil Italy
Brulamycin Germany, Hungary
Eltol India
Fytobra India
Gernebcin Germany
Komitob India
Nebcin Australia, Egypt, Great Britain, Greece, New Zealand, Republic of South Africa, Saudi Arabia
Nebcina Denmark, Morocco, Norway, Sweden
Nebcine France, Morocco
Nebicina Italy
Obracin Belgium, Luxembourg, Netherlands, Switzerland
Tobel Turkey
Tobra Germany
Tobra-Gobens Spain
Tobraalex Egypt
Tobracin Egypt
Tobradistin Spain
Tobramicina Italy, Portugal, Spain
Tobramina Brazil
Tobramycin Australia, Canada, Germany, Great Britain, Ireland, Norway, United States of America
Tobramycine Belgium, Luxembourg, Netherlands
Tobrasix Austria
Tobrazid Germany
Tomycin Finland
Stability of mixtures   Injection   Stability of mixtures : Tobramycin sulfate     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Glass Glucose 5% 3,2 mg/ml
Injection   Tobramycin sulfate   
Injection   Filgrastim 40 µg/ml
25°C
4 Hour
Not specified 104
Level of evidence B
Glass None 0,8 mg/ml
Injection   Tobramycin sulfate   
Injection   Ofloxacin 2 mg/ml
25°C
48 Hour
Not specified 889
Level of evidence D
Polyvinyl chloride NaCl 0,9% or Glucose 5% 1 mg/ml
Injection   Tobramycin sulfate   
Injection   Ciprofloxacin lactate 1,5 mg/ml
25°C
48 Hour
Light 434
Polyvinyl chloride NaCl 0,9% or Glucose 5% 0,2 & 0,8 mg/ml
Injection   Tobramycin sulfate   
Injection   Aztreonam 10 & 20 mg/ml
25°C
48 Hour
Not specified 19
Level of evidence D
Polyvinyl chloride NaCl 0,9% or Glucose 5% 0,2 mg/ml
Injection   Tobramycin sulfate   
Injection   Aztreonam 10 & 20 mg/ml
4°C
7 Day
Protect from light 19
Level of evidence D
Polyvinyl chloride NaCl 0,9% or Glucose 5% 0,2 & 0,8 mg/ml
Injection   Tobramycin sulfate   
Injection   Aztreonam 10 & 20 mg/ml
4°C
7 Day
Protect from light 19
Level of evidence D
Polyvinyl chloride NaCl 0,9% or Glucose 5% 1 mg/ml
Injection   Tobramycin sulfate   
Injection   Ciprofloxacin lactate 1,5 mg/ml
4°C
48 Hour
Protect from light 434
Polyvinyl chloride Sodium chloride 0,9% 1,2 mg/ml
Injection   Tobramycin sulfate   
Injection   Clindamycin phosphate 9 mg/ml
-20°C
28 Day
Protect from light 565
Level of evidence D
Polyvinyl chloride Glucose 5% 1,2 mg/ml
Injection   Tobramycin sulfate   
Injection   Clindamycin phosphate 9 mg/ml
-20°C
14 Day
Protect from light 565
Level of evidence D
Polyvinyl chloride Dianéal® PD2 2.5% glucose (Baxter) 0,008 mg/ml
Injection   Tobramycin sulfate   
Injection   Ceftazidime 0,125 mg/ml
24°C
16 Hour
Not specified 2369
Level of evidence B
Polyvinyl chloride Dianéal® PD2 2.5% glucose (Baxter) 0,008 mg/ml
Injection   Tobramycin sulfate   
Injection   Ceftazidime 0,125 mg/ml
37°C
8 Hour
Not specified 2369
Level of evidence B
Polyolefine None 0,80 mg/ml
Injection   Tobramycin sulfate   
Injection   Linezolid 1,80 mg/ml
23°C
1 Day
Protect from light 2353
Level of evidence B+
Polyolefine None 0,80 mg/ml
Injection   Tobramycin sulfate   
Injection   Linezolid 1,80 mg/ml
4°C
7 Day
Protect from light 2353
Level of evidence B+
  Mentions Légales